Cabaletta Bio
CABA
63 hedge funds and large institutions have $135M invested in Cabaletta Bio in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 17 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
8.95% more ownership
Funds ownership: 67.45% → 76.4% (+8.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 68 → 63 (-5)
25% less capital invested
Capital invested by funds: $180M → $135M (-$44.6M)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
78% less call options, than puts
Call options by funds: $118K | Put options by funds: $546K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.48M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.47M |
| 3 |
Millennium Management
New York
|
+$1.12M |
| 4 |
Morgan Stanley
New York
|
+$840K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$676K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.19M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.88M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.78M |
| 4 |
CCM
CAAS Capital Management
New York
|
-$1.64M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.03M |
CABA Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q2 2021, worth a combined $135M — down 25% from $180M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CABA and 12 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 19 added.
The largest buyer was Ikarian Capital, adding an estimated $5.48M. The largest seller was BlackRock, cutting an estimated $7.19M.
- 63 institutional investors held Cabaletta Bio (CABA) as of Q2 2021, down from 68 in Q1 2021.
- Funds reported $135M of Cabaletta Bio stock for Q2 2021, down 25% quarter-over-quarter.
- 12 funds opened new Cabaletta Bio positions in Q2 2021 and 17 closed out, a net change of -5 holders.
- The largest Cabaletta Bio buyer in Q2 2021 was Ikarian Capital, an estimated $5.48M added.
- The largest Cabaletta Bio seller in Q2 2021 was BlackRock, an estimated $7.19M sold.
Based on aggregated 13F filings for Q2 2021.